89840-63-1

Upstream product

• 107-10-8 propylamine 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 908072-33-3 2-nitro-N-(prop-2-yn-1-yl)benzene-1-sulfonamide 
• 198572-71-3 N-(tert-butoxycarbonyl)-2-nitrobenzenesulfonamide 

Downstream Products

• 436095-50-0 2-amino-N-propylbenzenesulfonamide 
• 863968-75-6 N-(1-methyl-1H-pyrrol-2-yl)-2-nitro-N-propyl-benzenesulfonamide 
• 21639-10-1 2-amino-N-propylbenzenesulfonamide hydrochloride 
• 888969-40-2 2-[2-chloro-5-(2-ethoxy-vinyl)-pyrimidin-4-ylamino]-N-propyl-benzenesulfonamide 
• 761440-02-2 2-(5-bromo-2-chloro-pyrimidin-4-ylamino)-N-propyl-benzenesulfonamide 
• 888969-41-3 2-(2-chloro-pyrrolo[2,3-d]pyrimidin-7-yl)-N-propyl-benzenesulfonamide 

Relevant academic research and scientific papers

Synthesis of polyfunctional fatty amines from sophorolipid-derived 17-hydroxy oleic acid

A series of mono- and diamines and one triamine have been prepared using methyl 17-hydroxy oleate as the common starting material. The 1 7-hydroxy oleate is an abundant bioderived material obtained from acid alcoholysis of sophorolipids, which in turn are

One-pot synthesis ofN-substituted benzannulated triazolesviastable arene diazonium salts

A mild and effective one-pot synthesis of 1,2,3-benzotriazin-4(3H)-ones and benzothiatriazine-1,1(2H)-dioxide analogues has been developed. The method involves the diazotisation and subsequent cyclisation of 2-aminobenzamides and 2-aminobenzenesulfonamidesviastable diazonium salts, prepared using a polymer-supported nitrite reagent andp-tosic acid. The transformation was compatible with a wide range of aryl functional groups and amide/sulfonamide-substituents and was used for the synthesis of pharmaceutically important targets. The synthetic utility of the one-pot diazotisaton-cyclisation process was further demonstrated with the preparation of an α-amino acid containing 1,2,3-benzotriazin-4(3H)-one.

Carbazole compounds and therapeutic uses of the compounds

Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

Chemoselective hydrogenation reaction of unsaturated bonds in the presence of an o-nitrobenzenesulfonyl group

Chemoselective hydrogenation of unsaturated compounds bearing an o-nitrobenzenesulfonyl (Ns)-amide moiety, affording the corresponding saturated compounds, was accomplished efficiently without loss of the nitro group by using the Pd/MS3A catalyst and a H2 balloon. Partial hydrogenation of alkynes bearing an Ns group to corresponding cis alkenes was achieved with the combination of the Pd/BN catalyst and an additive (diethylenetriamine or acetic acid).

2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS

The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/ or Pyk2 mediated disorder or disease.

Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2

A series of 2-amino-9-aryl-7H-pyrrolo[2,3-d]pyrimidines were designed and synthesized as focal adhesion kinase (FAK) inhibitors using molecular modeling in conjunction with a co-crystal structure. Chemistry was developed to introduce functionality onto th